Core Viewpoint - Chengdu Xian Dao announced the termination of its major asset restructuring deal with Nanjing Haina Pharmaceutical Technology Co., Ltd. after failing to reach consensus on key terms [1][3]. Group 1: Transaction Details - Chengdu Xian Dao intended to acquire approximately 65% of Haina Pharmaceutical through a cash equity transfer [3]. - Despite signing a letter of intent and conducting due diligence, the parties could not agree on core terms such as price, management control, and future strategic direction [3]. - The termination of this deal signifies a setback for Haina Pharmaceutical's plans for an IPO, which had been under review since June 30, 2023, and was ultimately withdrawn on June 24, 2024 [4]. Group 2: Company Performance - Chengdu Xian Dao's financial performance has shown a decline since its IPO, with net profits reported as approximately 64.02 million, 63.38 million, 25.27 million, 40.72 million, and 51.36 million from 2020 to 2024 [5]. - The company's stock has experienced a decline, with a current price of 16.57 yuan per share compared to the initial offering price of 20.52 yuan [5]. - The controlling shareholder, JIN LI, plans to increase his stake in the company by investing between 25 million and 50 million yuan within the next 12 months, indicating confidence in the company's long-term value [5].

Core Viewpoint - The acquisition of 64.81% stake in Imexpharm Corporation (IMP) by Lijuz Group for 1.587 billion yuan has sparked market discussions primarily due to its high valuation [1]. Group 1: Acquisition Details - The transaction price corresponds to a price-to-earnings (P/E) ratio of 27.6 times IMP's projected net profit for 2024, significantly higher than Lijuz Group's own P/E ratio of 15 times [4]. - If calculated based on the annualized net profit for the first quarter of 2025, the dynamic P/E ratio rises to 29.7 times [4]. - The acquisition price represents a premium of 293.79% over IMP's net assets at the end of 2024, indicating a control premium and a bet on the potential of the Vietnamese pharmaceutical market [4]. Group 2: Company Background and Market Position - IMP, established in 1977, is a leading pharmaceutical company in Vietnam, with core products including antibiotics (first in market share) and cardiovascular drugs (fifth in market share), covering over 80% of medical institutions in Vietnam [4]. - In 2024, IMP reported revenue of 696 million yuan and a net profit of 88.83 million yuan; for the first quarter of 2025, revenue was 186 million yuan with a net profit of 20.61 million yuan [4]. Group 3: Strategic Rationale - The acquisition aims to complement Lijuz Group's existing product lines in antibiotics and cardiovascular drugs, allowing both companies to share research and development resources as well as sales channels [4]. - The Vietnamese pharmaceutical market is growing at an annual rate exceeding 10%, and IMP holds EU GMP certification, which could provide Lijuz Group with a gateway to Southeast Asian and European markets [4]. - Lijuz Group's revenue in 2024 decreased by 4.97% year-on-year, primarily due to price reductions from centralized procurement and a decline in demand for antiviral drugs, necessitating the search for new growth opportunities [4].